Survival Comparison Between Surgical Resection and Percutaneous Radiofrequency Ablation for Patients in Barcelona Clinic Liver Cancer Early Stage Hepatocellular Carcinoma

Overview

Journal Indian J Gastroenterol

Specialty Gastroenterology

Date 2012 Aug 31

PMID 22932964

Citations 13

Authors

Kiong-Ming Wong

Ming-Lun Yeh

Shih-Chung Chuang

Liang-Yen Wang

Zu-Yau Lin

Shinn-Cherng Chen

Jung-Fa Tsai

Shen-Nien Wang

Kung-Kai Kuo

Chia-Yen Dai

Ming-Lung Yu

King-The Lee

Wan-Long Chuang

Affiliations

Soon will be listed here.

Abstract

Aim: To compare the survival outcome between surgical resection (SR) and radiofrequency ablation (RFA) for Barcelona Clinic Liver Cancer (BCLC) early stage hepatocellular carcinoma (HCC).

Methods: The retrospective study enrolled eighty-two patients with newly diagnosed BCLC early HCC (single nodule, size ≦3 cm, and Child-Pugh class A) treated either surgically (n = 46) or with RFA (n = 36) from year 2004 to 2009. The patients' survival outcomes were compared.

Results: There were no significant differences in overall survival (OS) rates between SR and RFA (p = 0.204). The 3- and 5-year disease-free survival (DFS) rates were 65.8 % and 53.7 % respectively, in the SR group, which were significantly higher than those in the RFA group (34.8 % and 14.9 % respectively) (p = 0.009 and p = 0.001). In subgroup analysis, the DFS was similar between RFA and SR in patients with presentation of lower platelet count (≦100,000/mL) and smaller tumor size (tumor size ≦1 cm). Multivariate analysis showed SR as a procedure type was a significant predictive factor for DFS [HR = 2.26 (CI 1.462-5.227), p = 0.002].

Conclusion: SR yielded similar OS but better DFS when compared to RFA for patients with BCLC early HCC (single nodule, ≦3 cm and Child-Pugh class A). In subgroup patients with lower platelet count (≦100,000/mL) and smaller tumor size (tumor size ≦1 cm), DFS was similar between both treatments.

Citing Articles

Primary treatments for solitary hepatocellular carcinoma ≤ 3 cm: A systematic review and network meta-analysis.

Kim S, Kim K, Na B, Kim S, Oh R Ann Hepatobiliary Pancreat Surg. 2024; 28(4):397-411.

PMID: 39175140 PMC: 11599817. DOI: 10.14701/ahbps.24-103.

A Retrospective Cohort Analysis of Transarterial Chemoembolization for Hepatocellular Cancer at a Tertiary Center in Switzerland.

Haak F, Karli T, Takes M, Zech C, Kollmar O, Soysal S J Clin Med. 2024; 13(11).

PMID: 38892990 PMC: 11172573. DOI: 10.3390/jcm13113279.

Efficacy and safety of various primary treatment strategies for very early and early hepatocellular carcinoma: a network meta-analysis.

Yang S, Lin H, Song J Cancer Cell Int. 2021; 21(1):681.

PMID: 34923980 PMC: 8684647. DOI: 10.1186/s12935-021-02365-1.

Comparative efficacy of treatment strategies for hepatocellular carcinoma: systematic review and network meta-analysis.

Tian G, Yang S, Yuan J, Threapleton D, Zhao Q, Chen F BMJ Open. 2018; 8(10):e021269.

PMID: 30341113 PMC: 6196801. DOI: 10.1136/bmjopen-2017-021269.

Percutaneous Ablation for Hepatocellular Carcinoma: Comparison of Various Ablation Techniques and Surgery.

Shiina S, Sato K, Tateishi R, Shimizu M, Ohama H, Hatanaka T Can J Gastroenterol Hepatol. 2018; 2018:4756147.

PMID: 29974040 PMC: 6008833. DOI: 10.1155/2018/4756147.

References

Yang J, Lin C, Huang J, Dai C, Lin W, Ho C . Viral hepatitis infections in southern Taiwan: a multicenter community-based study. Kaohsiung J Med Sci. 2010; 26(9):461-9. DOI: 10.1016/S1607-551X(10)70073-5. View

Kudo M . Management of hepatocellular carcinoma: from prevention to molecular targeted therapy. Oncology. 2010; 78 Suppl 1:1-6. DOI: 10.1159/000315222. View

Choy P, Koea J, McCall J, Holden A, Osbourne M . The role of radiofrequency ablation in the treatment of primary and metastatic tumours of the liver: initial lessons learned. N Z Med J. 2002; 115(1159):U128. View

Choi D, Lim H, Rhim H, Kim Y, Lee W, Paik S . Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. Eur Radiol. 2006; 17(3):684-92. DOI: 10.1007/s00330-006-0461-5. View

Chuang W, Yu M, Dai C, Chang W . Treatment of chronic hepatitis C in southern Taiwan. Intervirology. 2005; 49(1-2):99-106. DOI: 10.1159/000087271. View

Makuuchi M, Kokudo N . Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J Gastroenterol. 2006; 12(5):828-9. PMC: 4066144. DOI: 10.3748/wjg.v12.i5.828. View

Chen M, Li J, Zheng Y, Guo R, Liang H, Zhang Y . A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006; 243(3):321-8. PMC: 1448947. DOI: 10.1097/01.sla.0000201480.65519.b8. View

Maeda T, Takenaka K, Taguchi K, Kajiyama K, Shirabe K, Shimada M . Small hepatocellular carcinoma with minute satellite nodules. Hepatogastroenterology. 2000; 47(34):1063-6. View

Chen C, Yang P, Huang G, Lee H, Sung J, Sheu J . Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc. 2007; 106(2):148-55. DOI: 10.1016/S0929-6646(09)60231-X. View

10.

Wang J, Lu S, Wu J, Huang J, Yu M, Chen S . A hyperendemic community of hepatitis B virus and hepatitis C virus infection in Taiwan. Trans R Soc Trop Med Hyg. 1999; 93(3):253-4. DOI: 10.1016/s0035-9203(99)90012-3. View

11.

Lau W, Lai E . The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg. 2008; 249(1):20-5. DOI: 10.1097/SLA.0b013e31818eec29. View

12.

Dai C, Ho C, Huang J, Hsieh M, Hou N, Lin Z . Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan. J Hepatol. 2009; 52(2):160-6. DOI: 10.1016/j.jhep.2009.11.017. View

13.

Goto T, Yoshida H, Tateishi R, Enooku K, Goto E, Sato T . Influence of serum HBV DNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation. Hepatol Int. 2011; 5(3):767-73. DOI: 10.1007/s12072-011-9255-1. View

14.

Shi M, Guo R, Lin X, Zhang Y, Chen M, Zhang C . Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg. 2007; 245(1):36-43. PMC: 1867934. DOI: 10.1097/01.sla.0000231758.07868.71. View

15.

Scaife C, Ng C, Ellis L, Nicolas Vauthey J, Charnsangavej C, Curley S . Accuracy of preoperative imaging of hepatic tumors with helical computed tomography. Ann Surg Oncol. 2006; 13(4):542-6. DOI: 10.1245/ASO.2006.07.009. View

16.

Zhou Y, Zhao Y, Li B, Xu D, Yin Z, Xie F . Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol. 2010; 10:78. PMC: 2914087. DOI: 10.1186/1471-230X-10-78. View

17.

El-Serag H . Hepatocellular carcinoma. N Engl J Med. 2011; 365(12):1118-27. DOI: 10.1056/NEJMra1001683. View

18.

Wang J, Wang C, Hung C, Chen C, Lu S . Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol. 2011; 56(2):412-8. DOI: 10.1016/j.jhep.2011.05.020. View

19.

Lu S, Wang J, Liu S, Hung C, Chen C, Tung H . Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer. 2006; 107(9):2212-22. DOI: 10.1002/cncr.22242. View

20.

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View